AnHeart Therapeutics Announces Formation of Scientific Advisory Board
September 22, 2021
New York, NY/Hangzhou China – September 22, 2021 – AnHeart Therapeutics (“AnHeart”), a clinical-stage global biopharmaceutical company committed to developing novel cancer therapies, announced today the formation of its Scientific Advisory Board (SAB) comprised of world-renowned oncologists to provide external scientific review and high-level counsel on the Company’s research and development programs.
The SAB will work closely with the AnHeart leadership team, as the Company advances the clinical development of its lead investigational drug candidate taletrectinib, a next-generation investigational ROS1/NTRK inhibitor for non-small cell lung cancer (NSCLC).
“We are excited and privileged to have the opportunity to work with this group of leading oncologists on the development of our pipeline,” said Bing Yan, M.D., CMO and Co-founder of AnHeart Therapeutics. “These thought-leaders bring tremendous understanding of lung cancer and glioma, as well as extensive experience in drug development from discovery through to late-stage clinical trials. We look forward to their continued contributions as AnHeart enters a new stage in advancing taletrectinib into late-stage clinical trials this year.”
Members of the AnHeart Scientific Advisory Board are as follows:
Sai-Hong Ignatius Ou, M.D., Ph.D., Health Science Clinical Professor of Medicine in the Department of Medicine, Division of Hematology Oncology at the University of California Irvine School of Medicine
D. Ross Camidge, M.D., Ph.D., Joyce Zeff Chair in Lung Cancer Research, Director, Thoracic Oncology, University of Colorado, Anschutz Medical Campus
Caicun Zhou, M.D., Ph.D., Director of the Department of Oncology, Shanghai Pulmonary Hospital, Director of Cancer Institute of Tongji University Medical School, Chairman of the Oncology Department of Tongji University
David A. Reardon, M.D., Professor, Clinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard University
Takashi Seto, M.D., Director, National Kyushu Cancer Center, Thoracic Oncology / Clinical Oncology & Research, LC-SCRUM-Japan
About AnHeart Therapeutics
AnHeart is a clinical stage global biopharmaceutical company developing novel, first-in-class precision oncology therapeutics. Its lead candidate, taletrectinib, is a next-generation ROS1 and NTRK inhibitor currently in Phase 2 trials in first and second-line non-small cell lung cancer (NSCLC). AnHeart is developing a broad pipeline of next-generation precision oncology therapeutics in areas of high unmet medical need. For more information, please visit www.anhearttherapeutics.com.